Sector Expert: Jason Mills

Canaccord Genuity

Image: Jason Mills

Mr. Mills has been a publishing sell-side analyst with coverage of medical devices for over 15 years. His areas of coverage include Cardiovascular, Imaging/Robotics, Ophthalmology and Women's Healthcare. Mr. Mills joined Canaccord Genuity from First Albany Capital where he was managing director and senior medical devices analyst, and he previously served as a vice president and senior med-tech analyst with Thomas Weisel Partners (now part of Stifel), Mr. Mills has earned awards for his stock picking, including the #2 ranked Medical Devices analyst in the The Wall Street Journal's 2011 "Best on the Street" Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts. Mr. Mills holds a BA in Economics from Yale University and Master of Sports Administration from Ohio University.

Recent Interviews

Follow the M&A Money to Small- and Mid-Cap Cardiovascular Medtechs: Jason Mills (1/2/14)

Some investors' eyes glaze over at the mention of medical devices. But it's time to wake up and focus on the stunning growth opportunities in small- and mid-cap cardiovascular medtech. Canaccord Genuity Managing Director Jason Mills covers companies on the front lines of innovation and in sectors where the trifecta of revenue, margins and reimbursement is achieving biotechlike levels. In this interview with The Life Sciences Report, Mills opens the new year with a discussion of the cardiovascular medtech industry and mentions companies that are probable acquisition candidates.

Deep Value Found in Small Medtech: Jason Mills (4/19/12)

Medical device companies need to demonstrate four qualities to be good investment ideas, according to Senior Medical Devices Analyst and Managing Director Jason Mills of Canaccord Genuity. In this exclusive interview with The Life Sciences Report, Mills shares his precise criteria and pinpoints specific growth names that are trading at value levels.

Recent Quotes

"We believe EW is best positioned in TAVR among the current Big 2."

— Jason Mills, Canaccord Genuity (2/13/13)
more >

"EW's SAPIEN performed better with regard to PVL versus CoreValve."

— Jason Mills, Canaccord Genuity (9/4/12)
more >

"We reiterate our Buy rating for EW and are increasing our target price."

— Jason Mills, Canaccord Genuity (6/24/12)
more >

"We think this is a fantastic start to EW's U.S. TAVI launch."

— Jason Mills, Canaccord Genuity (5/1/12)
more >

"We're looking for EW's transcatheter valve franchise to grow 40–50% over the next two years."

The Life Sciences Report Interview with Jason Mills (4/18/12)
more >

"ISRG remains one of the best, most consistent growth companies in medtech."

— Jason Mills, Canaccord Genuity (4/16/12)
more >

"We believe results will support FDA approval of EW's SAPIEN."

— Jason Mills, Canaccord Genuity (3/26/12)
more >

Due to permission requirements, not all quotes are shown.